Blog
RSS FeedPosted by Michael Wonder on 06 Aug 2025
NICE approves first immunotherapy combination for endometrial cancer
6 August 2025 - Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, ...
Posted by Michael Wonder on 05 Aug 2025
Health technology assessment, again: a transparent, evidence-based approach for CMS drug price negotiations
4 August 2025 - The CMS can now negotiate the prices of a set of drugs that represent significant Medicare expenditures. ...
Posted by Michael Wonder on 04 Aug 2025
Update from the PBAC (July 2025)
4 August 2025 - The PBAC update following the July 2025 PBAC meeting is now available. ...
Posted by Michael Wonder on 02 Aug 2025
Seladelpar lysine dihydrate for the treatment of patients with primary biliary cholangitis
30 July 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 01 Aug 2025
Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2025
ICER to assess therapies for IgA nephropathy
31 July 2025 - Report will be subject of CTAF meeting in February 2026; draft scoping document open to public ...
Posted by Michael Wonder on 01 Aug 2025
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jul 2025
EMA CHMP adopts positive opinion recommending authorisation of Moderna's COVID-19 mRNA vaccine targeting the SARS-CoV-2 variant LP.8.1
25 July 2025 - Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European ...
Posted by Michael Wonder on 31 Jul 2025
Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma
29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Jul 2025
Agenda for the November 2025 PBAC meeting
30 July 2025 - The agenda for the November 2025 PBAC meeting is now available. ...
Posted by Michael Wonder on 30 Jul 2025
MSAC publishes agenda for November 2025 MSAC meeting
30 July 2025 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC ...
Posted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, ...
Posted by Michael Wonder on 29 Jul 2025
BeOne Medicines receives positive CHMP opinion for Tevimbra in neo-adjuvant/adjuvant NSCLC treatment
28 July 2025 - Recommendation based on Phase 3 RATIONALE-315 study, in which Tevimbra demonstrated clinically meaningful and statistically significant improvement ...
Posted by Michael Wonder on 28 Jul 2025
Highlights from the 21-24 July 2025 CHMP meeting
25 July 2025 - The EMA’s CHMP recommended 13 medicines for approval at its July 2025 meeting. ...
Posted by Michael Wonder on 28 Jul 2025
Dupilumab for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (review of TA648)
23 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...